Brought to you by 
Baxalta and Precision enter CART deal; Precision could get up to $1.6bn; Program Terminated
16 Nov 2021
Executive Summary
Baxalta Inc. and Precision BioSciences Inc. will use Precision's ARCUS platform to develop chimeric antigen receptor T-cell (CART) therapies for up to six unique cancer targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxalta and Precision enter CART deal; Precision could get up to $1.6bn; Program Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice